Line 56: |
Line 56: |
| The use of topical shampoos and washes can also be beneficial. As well as physically removing allergens from the skin and coat, moisturising shampoos can hydrate the skin and improve the lipid barrier. Colloidal oatmeal may also have a direct antipruritic action<sup>4</sup>. Anti-microbial or anti-scaling shampoos, and ear cleaners can prove useful in certain cases depending on presentation. | | The use of topical shampoos and washes can also be beneficial. As well as physically removing allergens from the skin and coat, moisturising shampoos can hydrate the skin and improve the lipid barrier. Colloidal oatmeal may also have a direct antipruritic action<sup>4</sup>. Anti-microbial or anti-scaling shampoos, and ear cleaners can prove useful in certain cases depending on presentation. |
| | | |
− | ====Essential fatty acids (EFA)====
| + | Essential fatty acids have been subjected to numerous clinical trials. EFA supplementation alters incorporation into cell membranes, which may reduce production of inflammatory leukotrienes and prostaglandins<sup>4</sup>. The cutaneous lipid may also be improved. However, there is some conflicting informtation, and high levels of supplementation may be neccessary to give beneficial effects. |
− | Numerous clinical trials and studies have evaluated
| |
− | EFAs particularly the n-3 EFA eicosapentenoic acid
| |
− | (EPA) and the n-6 EFA gamma-linolenic acid (GLA).
| |
− | Supplementation can result in altered plasma levels
| |
− | and incorporation into cell membranes, which may
| |
− | lead to production of less inflammatory leucotrienes
| |
− | and prostaglandins and improved cutaneous lipid | |
− | barrier. Recent studies, however, have not found
| |
− | consistent changes in plasma, subcutaneous fat or
| |
− | cutaneous EFAs following supplementation in atopic
| |
− | and healthy dogs, and no correlation with the | |
− | clinical response (1-3).
| |
− | Clinical results have been variable in controlled
| |
− | trials, and no relationship between efficacy and
| |
− | ratio of n-3/n-6 EFAs have been proven, although
| |
− | high doses seem to be more effective. Recent
| |
− | studies have shown that high quality, EFA enriched
| |
− | diets are beneficial in canine AD although how
| |
− | much of this is due to anti-inflammatory activity
| |
− | or cutaneous barrier improvements is unclear (4).
| |
| | | |
| ===Allergen specific therapy=== | | ===Allergen specific therapy=== |